Serina Therapeutics Financials
This page shows Serina Therapeutics (ser) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Serina Therapeutics has an operating margin of -30442.9%, meaning the company retains $-30443 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -99.2% the prior year.
Serina Therapeutics's revenue declined 98.2% year-over-year, from $3.2M to $56K. This contraction results in a growth score of 0/100.
Serina Therapeutics has elevated debt relative to equity (D/E of 9.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 2.40, Serina Therapeutics holds $2.40 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.
While Serina Therapeutics generated -$17.1M in operating cash flow, capex of $22K consumed most of it, leaving -$17.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Serina Therapeutics passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Serina Therapeutics generates $1.54 in operating cash flow (-$17.1M OCF vs -$11.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Serina Therapeutics earns $-32.4 in operating income for every $1 of interest expense (-$17.0M vs $526K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Serina Therapeutics generated $56K in revenue in fiscal year 2024. This represents a decrease of 98.2% from the prior year.
Serina Therapeutics's EBITDA was -$16.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 454.6% from the prior year.
Serina Therapeutics generated -$17.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 475.8% from the prior year.
Serina Therapeutics reported -$11.1M in net income in fiscal year 2024. This represents a decrease of 311.4% from the prior year.
Serina Therapeutics earned $-1.51 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 306.8% from the prior year.
Serina Therapeutics held $3.7M in cash against $0 in long-term debt as of fiscal year 2024.
Serina Therapeutics had 9M shares outstanding in fiscal year 2024. This represents an increase of 291.0% from the prior year.
Serina Therapeutics's operating margin was -30442.9% in fiscal year 2024, reflecting core business profitability. This is down 30343.6 percentage points from the prior year.
Serina Therapeutics's net profit margin was -19894.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 20061.8 percentage points from the prior year.
Serina Therapeutics invested $7.5M in research and development in fiscal year 2024. This represents an increase of 213.2% from the prior year.
Serina Therapeutics invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 95.6% from the prior year.
ser Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $130K | $0-100.0% | $549K+3821.4% | $14K-72.5% | $51K+920.0% | $5K-99.8% | $3.1M |
| Cost of Revenue | N/A | N/A | N/A | $79K+61.2% | $49K-7.5% | $53K-15.9% | $63K+6200.0% | $1K |
| Gross Profit | N/A | N/A | N/A | $470K+1442.9% | -$35K-1650.0% | -$2K+96.6% | -$58K-162.4% | $93K |
| R&D Expenses | $3.7M+15.8% | $3.2M+6.8% | $3.0M+100.9% | $1.5M-39.2% | $2.4M+51.5% | $1.6M+44.1% | $1.1M+21.9% | $907K |
| SG&A Expenses | $2.7M+7.8% | $2.5M-12.5% | $2.9M+69.3% | $1.7M-41.0% | $2.9M+25.3% | $2.3M+90.4% | $1.2M-37.1% | $1.9M |
| Operating Income | -$6.4M-14.9% | -$5.6M+5.0% | -$5.9M-115.7% | -$2.7M+48.9% | -$5.3M-37.4% | -$3.9M-66.6% | -$2.3M-1063.1% | $241K |
| Interest Expense | $6K-33.3% | $9K | $0 | N/A | $16K-94.8% | $307K+210.1% | $99K-90.0% | $986K |
| Income Tax | N/A | N/A | N/A | $18K-66.7% | $54K+1700.0% | $3K-95.9% | $73K | $0 |
| Net Income | -$4.6M+28.9% | -$6.4M-34.0% | -$4.8M-77.5% | -$2.7M-292.3% | $1.4M-72.9% | $5.2M+134.7% | -$15.0M-1528.6% | $1.1M |
| EPS (Diluted) | $-0.45+31.8% | $-0.66-34.7% | $-0.49 | N/A | $0.13-74.5% | $0.51+109.5% | $-5.38 | N/A |
ser Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.4M+38.8% | $8.9M+32.8% | $6.7M+0.1% | $6.7M-9.6% | $7.4M-30.6% | $10.7M-1.4% | $10.9M+21.1% | $9.0M |
| Current Assets | $11.5M+43.9% | $8.0M+38.9% | $5.8M+1.4% | $5.7M+4.7% | $5.4M-39.2% | $8.9M-0.2% | $8.9M+17.3% | $7.6M |
| Cash & Equivalents | $8.6M+42.7% | $6.0M+41.6% | $4.3M+16.2% | $3.7M+15.3% | $3.2M-47.5% | $6.1M-30.3% | $8.7M+14.3% | $7.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $363K+55.1% | $234K+12.5% | $208K+220.0% | $65K+14.0% | $57K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.8M+48.3% | $7.3M+41.0% | $5.2M-16.8% | $6.2M-70.8% | $21.3M-21.5% | $27.1M+78.7% | $15.2M-63.2% | $41.3M |
| Current Liabilities | $8.8M+146.8% | $3.6M+51.4% | $2.4M-0.6% | $2.4M-82.5% | $13.5M+7.0% | $12.6M-10.1% | $14.1M+895.0% | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $11.2M | N/A | N/A | N/A |
| Total Equity | $1.8M-2.3% | $1.8M+5.9% | $1.7M+165.4% | $641K+104.7% | -$13.8M+15.8% | -$16.4M-279.7% | -$4.3M+86.7% | -$32.3M |
| Retained Earnings | -$60.2M-8.2% | -$55.6M-13.1% | -$49.1M-10.9% | -$44.3M-6.6% | -$41.6M+3.3% | -$43.0M+10.8% | -$48.2M-45.3% | -$33.2M |
ser Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M-2.7% | -$3.8M+13.2% | -$4.3M+5.8% | -$4.6M-54.9% | -$3.0M+63.0% | -$8.0M-407.9% | -$1.6M-1403.3% | $121K |
| Capital Expenditures | $13K-71.7% | $46K | $0-100.0% | $5K+66.7% | $3K | $0-100.0% | $14K-80.0% | $70K |
| Free Cash Flow | -$3.9M-1.8% | -$3.8M+12.2% | -$4.3M+5.9% | -$4.6M-54.9% | -$3.0M+63.0% | -$8.0M-403.4% | -$1.6M-3219.6% | $51K |
| Investing Cash Flow | -$13K+71.7% | -$46K | $0+100.0% | -$5K-66.7% | -$3K | $0+100.0% | -$14K+80.0% | -$70K |
| Financing Cash Flow | $6.4M+15.7% | $5.6M+13.3% | $4.9M-2.3% | $5.0M+5750.0% | $86K-98.4% | $5.4M+96.7% | $2.7M+21084.6% | -$13K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ser Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 85.6%+335.6pp | -250.0%-246.1pp | -3.9%+1156.1pp | -1160.0%-1163.0pp | 3.0% |
| Operating Margin | N/A | -4280.8% | N/A | -494.7%+37448.1pp | -37942.9%-30362.5pp | -7580.4%+38839.6pp | -46420.0%-46427.8pp | 7.8% |
| Net Margin | N/A | -4960.0% | N/A | -493.8%-10565.2pp | 10071.4%-132.5pp | 10203.9%+310503.9pp | -300300.0%-300334.0pp | 34.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -36.9%+35.2pp | -72.1%-0.6pp | -71.5%-35.1pp | -36.4%-55.4pp | 19.0%-29.6pp | 48.6%+186.9pp | -138.3%-150.0pp | 11.7% |
| Current Ratio | 1.31-0.9 | 2.24-0.2 | 2.45+0.0 | 2.40+2.0 | 0.40-0.3 | 0.71+0.1 | 0.64-4.8 | 5.39 |
| Debt-to-Equity | 6.15+2.1 | 4.05+1.0 | 3.04-6.7 | 9.70+10.5 | -0.81+0.8 | -1.66+1.9 | -3.52-2.2 | -1.28 |
| FCF Margin | N/A | -2920.0% | N/A | -492.9%+20685.7pp | -21178.6%-5474.6pp | -15703.9%+16116.1pp | -31820.0%-31821.7pp | 1.7% |
Similar Companies
Frequently Asked Questions
What is Serina Therapeutics's annual revenue?
Serina Therapeutics (ser) reported $56K in total revenue for fiscal year 2024. This represents a -98.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Serina Therapeutics's revenue growing?
Serina Therapeutics (ser) revenue declined by 98.2% year-over-year, from $3.2M to $56K in fiscal year 2024.
Is Serina Therapeutics profitable?
No, Serina Therapeutics (ser) reported a net income of -$11.1M in fiscal year 2024, with a net profit margin of -19894.6%.
What is Serina Therapeutics's earnings per share (EPS)?
Serina Therapeutics (ser) reported diluted earnings per share of $-1.51 for fiscal year 2024. This represents a -306.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Serina Therapeutics's EBITDA?
Serina Therapeutics (ser) had EBITDA of -$16.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Serina Therapeutics's operating margin?
Serina Therapeutics (ser) had an operating margin of -30442.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Serina Therapeutics's net profit margin?
Serina Therapeutics (ser) had a net profit margin of -19894.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Serina Therapeutics's free cash flow?
Serina Therapeutics (ser) generated -$17.2M in free cash flow during fiscal year 2024. This represents a -475.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Serina Therapeutics's operating cash flow?
Serina Therapeutics (ser) generated -$17.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Serina Therapeutics's total assets?
Serina Therapeutics (ser) had $6.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Serina Therapeutics's capital expenditures?
Serina Therapeutics (ser) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Serina Therapeutics spend on research and development?
Serina Therapeutics (ser) invested $7.5M in research and development during fiscal year 2024.
How many shares does Serina Therapeutics have outstanding?
Serina Therapeutics (ser) had 9M shares outstanding as of fiscal year 2024.
What is Serina Therapeutics's current ratio?
Serina Therapeutics (ser) had a current ratio of 2.40 as of fiscal year 2024, which is generally considered healthy.
What is Serina Therapeutics's debt-to-equity ratio?
Serina Therapeutics (ser) had a debt-to-equity ratio of 9.70 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Serina Therapeutics's return on assets (ROA)?
Serina Therapeutics (ser) had a return on assets of -165.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Serina Therapeutics's cash runway?
Based on fiscal year 2024 data, Serina Therapeutics (ser) had $3.7M in cash against an annual operating cash burn of $17.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Serina Therapeutics's Piotroski F-Score?
Serina Therapeutics (ser) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Serina Therapeutics's earnings high quality?
Serina Therapeutics (ser) has an earnings quality ratio of 1.54x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Serina Therapeutics cover its interest payments?
Serina Therapeutics (ser) has an interest coverage ratio of -32.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Serina Therapeutics?
Serina Therapeutics (ser) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.